Choose Your Country or Region

Myoferlin Rabbit mAb

Catalog No.: F3596

Application: Reactivity: Mouse, Rat, Human

Usage Information

Dilution
WB1:2000 IF1:100 FCM1:400

Application
WB, IF, FCM

Reactivity
Mouse, Rat, Human

Source
Rabbit

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
235 kDa 180 kDa,250 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight.

Datasheet & SDS

Biological Description

Specificity
Myoferlin Rabbit mAb detects endogenous levels of total Myoferlin protein.

Clone
M11L18

Synonym(s)
FER1L3, KIAA1207, MYOF, Myoferlin, Fer-1-like protein 3

Background
Myoferlin is a membrane-anchored protein belonging to the ferlin family, encoded by a gene located on chromosome 10q23.33. It shares 69% sequence similarity with dysferlin, a protein whose mutations are linked to Miyoshi myopathy and limb-girdle muscular dystrophy type 2B. Members of the ferlin family—including dysferlin, myoferlin, otoferlin, Fer1L5, and Fer1L6—are characterized by multiple C2 domains and a single-pass transmembrane domain at the C-terminus. Myoferlin and dysferlin are the most structurally similar, each being ~230 kDa, containing seven C2 domains and a DYSF domain, and showing high expression in myoblasts. Functionally, myoferlin is active in various cell types, including myoblasts and endothelial cells. In cancer, it has emerged as a potential biomarker and therapeutic target in malignancies such as non–small-cell lung cancer, breast cancer, pancreatic adenocarcinoma, hepatocellular carcinoma, colorectal cancer, melanoma, head and neck squamous cell carcinoma, clear cell renal cell carcinoma, and endometrioid carcinoma. Mechanistically, myoferlin contributes to tumor progression by promoting angiogenesis, vasculogenic mimicry, metabolic reprogramming, epithelial–mesenchymal transition, and exosome modulation. Its roles in both physiological and pathological contexts highlight its significance as a candidate for novel cancer treatment strategies.

Background

Myoferlin is a membrane-anchored protein belonging to the ferlin family, encoded by a gene located on chromosome 10q23.33. It shares 69% sequence similarity with dysferlin, a protein whose mutations are linked to Miyoshi myopathy and limb-girdle muscular dystrophy type 2B. Members of the ferlin family—including dysferlin, myoferlin, otoferlin, Fer1L5, and Fer1L6—are characterized by multiple C2 domains and a single-pass transmembrane domain at the C-terminus. Myoferlin and dysferlin are the most structurally similar, each being ~230 kDa, containing seven C2 domains and a DYSF domain, and showing high expression in myoblasts. Functionally, myoferlin is active in various cell types, including myoblasts and endothelial cells. In cancer, it has emerged as a potential biomarker and therapeutic target in malignancies such as non–small-cell lung cancer, breast cancer, pancreatic adenocarcinoma, hepatocellular carcinoma, colorectal cancer, melanoma, head and neck squamous cell carcinoma, clear cell renal cell carcinoma, and endometrioid carcinoma. Mechanistically, myoferlin contributes to tumor progression by promoting angiogenesis, vasculogenic mimicry, metabolic reprogramming, epithelial–mesenchymal transition, and exosome modulation. Its roles in both physiological and pathological contexts highlight its significance as a candidate for novel cancer treatment strategies.

References
https://pubmed.ncbi.nlm.nih.gov/31475450/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%